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The longstanding Langerhans cell (LC) para-
digm (Schuler and Steinman, 1985; Wilson and 
Villadangos, 2004) holds that LCs acquire skin-
associated antigens and present them to T cells 
upon migrating to skin-draining lymph nodes. 
However, a series of recent studies using trans-
genic mouse models has failed to clearly dem-
onstrate a critical contribution of LCs in the 
induction of immunity to percutaneous anti-
gens in vivo.
LCs were dispensable for antiviral immu-
nity in a herpes simplex virus skin scarification 
model (Allan et al., 2003), and mouse models 
in which LCs were transiently or constitutively 
depleted showed that they were not essential for 
eliciting hapten-induced contact hypersensitiv-
ity (Kaplan et al., 2005; Kissenpfennig et al., 
2005; Bennett et al., 2007). It is possible that LCs 
are tolerogenic, but this may depend on the na-
ture of the antigen (e.g., foreign or self), route 
of antigen exposure (e.g., through the epidermis 
or directly into the dermis), and presence or 
absence of environmental cues, including inter-
actions with pathogens (Kautz-Neu et al., 2011).
We  recently  reported  that  LCs  induced 
IgG1 (Th2) responses to gene gun–immunized 
bacterial antigens and that skin DC subsets had 
distinct  roles  in  inducing  humoral  responses 
(Nagao et al., 2009). Although this experimental 
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Epidermal Langerhans cells (LCs) extend dendrites through tight junctions (TJs) to survey 
the skin surface, but their immunological contribution in vivo remains elusive. We show 
that LCs were essential for inducing IgG1 responses to patch-immunized ovalbumin in mice 
that lacked skin dendritic cell subsets. The significance of LC-induced humoral responses 
was demonstrated in a mouse model of staphylococcal scalded skin syndrome (SSSS), a severe 
blistering disease in which the desmosomal protein Dsg1 (desmoglein1) is cleaved by 
Staphylococcus aureus–derived exfoliative toxin (ET). Importantly, ET did not penetrate TJs, 
and patch immunization did not alter epidermal integrity. Nevertheless, neutralizing anti-
ET IgG1 was induced after patch immunization and abolished upon LC depletion, indicating 
that antigen capture through TJs by LCs induced humoral immunity. Strikingly, the ET-patched 
mice were protected from developing SSSS after intraperitoneal ET challenge, whereas LC-
depleted mice were susceptible to SSSS, demonstrating a vital role for LC-induced IgG1 in 
systemic defense against circulating toxin in vivo. Therefore, LCs elicit humoral immunity 
to antigens that have not yet violated the epidermal barrier, providing preemptive immunity 
against potentially pathogenic skin microbes. Targeting this immunological process confers 
protection with minimal invasiveness and should have a marked impact on future strategies 
for development of percutaneous vaccines.
© 2011 Ouchi et al.  This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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(SSSS), a severe blistering disease caused by exfoliative toxin 
(ET)–producing Staphylococcus aureus (Stanley and Amagai, 
2006), to further demonstrate the critical role of LCs in pro-
tective immunity in vivo.
RESULTS AND DISCUSSION
To test whether ACT by LCs leads to antigen-specific IgG1 re-
sponses  against  protein  antigens,  we  patch-immunized  WT 
C57BL/6 mice with OVA three times at 5-d intervals and de-
termined serum anti-OVA antibody levels by ELISA (Fig. 1 A). 
TJs regulate paracellular trafficking of ions and do not allow pas-
sage of soluble proteins (Vermeer et al., 2003). Therefore, OVA 
procedure represented in vivo data with antigen specificity, it 
circumvented  the  epidermal  barrier  system  and  antigen 
uptake processes. Our subsequent study demonstrated that 
LCs extend dendrites through the tight junctions (TJs) to the 
stratum corneum and capture protein antigens without dis-
turbing barrier integrity (Kubo et al., 2009). These findings 
indicate that LCs survey not only within the skin but also on 
the skin surface outside of the TJs. In this study, we focused 
on antigen capture through TJs (ACT) by LCs to determine 
whether these enigmatic skin DCs are capable of inducing 
immune responses to percutaneous protein antigens. We used 
a model of experimental staphylococcal scalded skin syndrome 
Figure 1.  LCs are essential for the induction of IgG1 responses to OVA captured through TJs. (A) Patch immunization protocol. 4 mg/ml OVA in 
PBS was used to patch immunize mice via an occlusive dressing on the gently tape-stripped ears (yellow); the patch was removed after 24 h. In DC deple-
tion experiments, DT was administered i.p. to mice 24 h before each patch immunization. (B) OVA-specific IgG1 responses were determined by ELISA of 
sera (1:500 dilution) from mice that received OVA i.p. (n = 13), OVA-patched WT mice (n = 10), Langerin-DTR mice without DT i.p. (n = 10), Langerin-DTR 
mice with DT i.p. (n = 17), and PBS-patched (n = 8) WT mice. ***, P = 0.0006 (second lane vs. fourth lane) and P = 0.0008 (third lane vs. fourth lane) by 
Student’s t test. Shown are results from a single experiment representative of three experiments. (C) Lethally irradiated recipient mice were reconstituted 
with BM from the indicated donor mice. After complete chimerism, the mice were treated with DT i.p. to generate mice that harbored (top; WT → WT) or 
lacked (bottom; CD11c-DTR → L-DTR) all skin DCs and mice that lacked only langerin+ dDCs (middle; L-DTR → WT). BMT, BM transfer. (D) OVA-specific 
IgG1 responses in sera (1:500 dilution) of mice from C. n = 10 WT → WT, n = 8 L-DTR → WT, and n = 9 CD11c-DTR → L-DTR mice from a single experi-
ment that was reproduced in a similar, independent experiment. **, P = 0.0035 (first lane vs. third lane) and P = 0.0017 (second lane vs. third lane) by 
Student’s t test. (B and D) Error bars represent mean value ± SEM.JEM Vol. 208, No. 13  2609
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or all DCs (CD11c-DTR BM → Langerin-DTR) were 
depleted, as well as mice that harbored all DCs (WT BM → 
WT; Fig. 1 C and Fig. S1). As LCs are radio resistant (Merad 
et al., 2002), lethally irradiated WT mice chimerized with 
Langerin-DTR BM could be depleted of langerin+ dDCs 
upon DT treatment, whereas the LCs of host origin remained 
unaffected in the epidermis.
Robust anti-OVA responses were observed in mice that 
harbored all DCs, in contrast to mice that lacked all DCs 
(Fig. 1 D). Of note, mice that lacked langerin+ dDCs res-
ponded with anti-OVA IgG1 levels similar to those of mice 
harboring all DCs (Fig. 1 D). These results demonstrate an 
essential role for LCs but not dDCs in inducing antigen-
specific IgG1 responses subsequent to ACT.
The aforementioned results led us to wonder whether LCs 
performed ACT to survey for antigens from bacterial flora that 
could exert pathogenicity under certain conditions. S. aureus is a 
clinically relevant bacterium that is capable of colonizing and/or 
infecting skin, and SSSS is a severe blistering disease that occurs 
during childhood, caused by skin infection with S. aureus that   
produces ET (Stanley and Amagai, 2006). ET circulates systemi-
cally via the bloodstream to distal skin sites (Nishioka et al., 
1977b; Ladhani et al., 1999), where it cleaves Dsg1 (desmo-
glein1), a desmosomal adhesion molecule of the cadherin family   
does not pass through TJs but can be taken up by LCs across the 
TJ barrier, as we have recently shown (Kubo et al., 2009).
Consistent with our previous results using gene gun immu-
nization (Nagao et al., 2009), WT mice produced OVA-specific 
antibodies restricted to the IgG1 subclass (Fig. 1 B). To deter-
mine the contribution of LCs, we used Langerin-DTR 
(diphtheria toxin [DT] receptor) mice (Bennett et al., 2005), in 
which langerin-expressing cells are selectively and transiently 
depleted upon DT treatment. Langerin+ dermal DCs (dDCs), 
a recently described dDC subset (Bursch et al., 2007; Ginhoux 
et al., 2007; Poulin et al., 2007), do not repopulate the dermis 
for 3–7 d, and LCs do not repopulate the epidermis for at least   
2 wk during steady-state after conditional depletion (Nagao 
et al., 2009; Noordegraaf et al., 2010). Langerin-DTR mice re-
ceived i.p. DT 1 d before each patch immunization (Fig. 1 A). 
In contrast to the robust IgG1 responses obtained in WT and 
DT-untreated Langerin-DTR mice, the responses were abol-
ished in DT-treated Langerin-DTR mice, demonstrating that 
langerin-expressing DCs were required for humoral responses to 
patch-immunized protein antigens (Fig. 1 B).
Given that langerin+ dDCs are also depleted in this ex-
perimental setting (Nagao et al., 2009), we combined con-
ditional depletion and BM transplantation to generate mice 
in which only langerin+ dDCs (Langerin-DTR BM → WT) 
Figure 2.  Patch-immunized ETA does not alter epidermal integrity. (A) Development of SSSS 3 h after i.p. injection of ETA. (B) Histological features 
of superficial acantholysis in experimental SSSS. The asterisk denotes blister formation. (C) Visualization of Dsg1 and TJs in ear skin after intradermal (i.d.) 
injection of PBS or ETA. Dsg1 (red) and TJs (shown via ZO-1 staining in green; arrows) were visualized in the periphery of the blister in ear skin denoted by 
the asterisk (bottom) that received ETA intradermally (right). (D) Histological features of ear skin that received PBS or ETA patch immunization for 1, 3, or 
24 h (right). Each experiment was performed three times with n = 3. Bars: (A) 1 cm; (B, C [left], and D) 25 µm; (C, right) 10 µm.2610 LC-induced humoral responses | Ouchi et al.
severity as soon as 3 h after treatment (Fig. 2 A). Epidermal 
detachment in the granular layer, identical to that seen in human 
SSSS, was confirmed by histology (Fig. 2 B; Amagai et al., 
2000; Stanley and Amagai, 2006). We then determined that 
TJs do not allow penetration of ETA. When ETA was injected 
into the dermis, it cleaved Dsg1 on keratinocytes located 
below but not above the TJ barrier (as visualized by ZO-1; 
Fig. 2 C). Moreover, tape-stripped skin to which ETA was 
patch immunized for 1, 3, or 24 h remained intact, with no 
clinical or histological sign of acantholysis (Fig. 2 D). These 
findings showed that ETA did not penetrate the epidermal 
barrier system to reach the viable layers, further suggesting 
that any immune responses achieved after ETA patch immu-
nization are likely attributable to ACT by LCs.
which is critical for maintaining cell–cell adhesion in the upper 
epidermis (Amagai et al., 2000; Stanley and Amagai, 2006).
Anti-ET antibodies can be detected in healthy individuals 
with no history of SSSS (Yamasaki et al., 2005), and it has been 
suggested that the presence or absence of circulating anti-ET 
antibodies may affect disease severity (Nishioka et al., 1977b; 
Ladhani  et  al.,  1999).  Therefore,  we  sought  to  determine 
whether LCs were capable of capturing S. aureus–derived ET 
through intact TJs and subsequently prepare a repertoire of 
antibodies that conferred protection from SSSS development.
We  modified  a  mouse  model  of  experimental  SSSS 
(Nishioka et al., 1977a) by using recombinant ETA, which is a 
major isoform of ET along with ETB, in adult mice. A single i.p. 
injection of ETA induced skin erosions with dose-dependent 
Figure 3.  ACT by LCs confers protective and systemic humoral immunity against experimental SSSS. (A) The anti-ETA IgG1 response in WT 
mice that received ETA i.p., PBS patch, or ETA patch, as well as Langerin-DTR mice that were treated with DT 1 d before each ETA patch immunization. 
Sera were diluted 1:500. **, P = 0.0024. (B) Cleavage analysis of hrDsg1. ETA was preincubated with purified IgG from mice patch immunized with 
either PBS (PBS-IgG) or ETA (ETA-IgG) and then further incubated with hrDsg1. Each lane represents IgG purified from a single mouse. The arrow de-
notes hrDsg1, 75 kD in size. (C) Dose dependency of the neutralizing activity of ETA-IgG. (D) PBS patch-immunized WT mice (n = 16), ETA patch-
immunized WT mice (n = 14), and DT-treated, ETA patch-immunized Langerin-DTR mice (n = 15) from A were challenged i.p. with 200 µg ETA, and 
images were taken 3 h later. Shown are representative data from a single experiment. Bar, 1 cm. Experiments in A–C were performed in two other 
independent experiments and D in one other experiment with similar results. (E) Erosion area index of ventral trunk skin in mice from D. *, P = 0.0432; 
***, P = 0.0003. (A and E) Error bars represent mean value ± SEM.JEM Vol. 208, No. 13  2611
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mice were obtained by breeding homozygous Langerin-DTR mice with 
C57BL/6J WT mice. CD11c-DTR mice were a gift from D.R. Littman 
(New York University School of Medicine, New York, NY). All animal 
procedures and study protocols were approved by the Keio University Ethics 
Committee for Animal Experiments.
Genomic PCR of Langerin-DTR mice. The langerin WT allele was detected   
using  the  primers  LangWTf1  (5-TGCTTCTGCCCACAACTGCTCTT-3) 
and  LangWTb1  (5-GACACCAAGGACTGTAGCCAAAAGG-3).  The 
langerin-DTR  allele  was  detected  by  using  LangWTf1  and  LangDTR2 
(5-TCAGTGGGAATTAGTCATGCC-3).
In vivo depletion of langerin+ DCs. For in vivo depletion of langerin+ 
DCs, heterozygous Langerin-DTR mice were injected i.p. with 500 ng DT 
(Sigma-Aldrich) in sterile PBS.
Patch immunization. The dorsal mouse ears were gently tape-stripped 
five times with Scotch tape (3M), and double-layered filter paper wetted 
with 50 µl of 4 mg/ml OVA or ETA in PBS was used to patch immunize 
the mice, using a patch device (Finn Chamber; SmartPractice). The mice 
were fitted with plastic collars to avoid scratching of the immunization sites. 
The Finn Chambers were removed after 24 h, but the collars were kept on 
for 2 or 3 d to prevent the mice scratching their ears. Immunization was 
performed three times at 5-d intervals, and the ear that received patch 
immunization was switched each time from right to left or vice versa to 
prevent any inadvertent damage to the immunization site. Sera were col-
lected 5 d after the final immunization.
ELISA. The wells of MaxiSorp ELISA plates (Thermo Fisher Scientific) 
were coated with OVA or ET (50 ng/well) at 4°C overnight. After blocking, 
sera were serially diluted 1:500 in PBS containing 3% skim milk and added 
to the wells. The plates were incubated for 2 h at room temperature. After 
washing, the plates were incubated with horseradish peroxidase–conjugated 
goat anti–mouse IgG1/2b/2c/3 antibodies (Bethyl Laboratories, Inc.) for 2 h. 
Immunoreactivity was detected with TMB substrate solution (MBL), and 
enzymatic reactions were halted with 1 M NH2SO4 before measuring the opti-
cal density at 450 nm.
Generation of BM chimeric mice. 8-wk-old recipient C57BL/6 and/or 
Langerin-DTR mice were lethally irradiated (9.5 Gy) and reconstituted with 
2 × 106 BM cells from C57BL/6, Langerin-DTR, or CD11c-DTR mice.
Antibodies. Rat anti–mouse EpCAM mAb (clone G8.8; Developmental 
Studies Hybridoma Bank) labeled with Alexa Fluor 568 (Invitrogen), rat anti–
mouse langerin mAb (clone L31; provided by C.-G. Park and R. Steinman, 
The Rockefeller University, New York, NY) labeled with Alexa Fluor 647 
(Invitrogen),  and  FITC-conjugated  rat  anti–mouse  I-A/I-E  mAb  (clone 
M5/114.15.2; BioLegend) for detection of MHC class II were used for immuno-
histochemistry of epidermal and dermal sheets. Anti–mouse CD16/32 mAb 
(clone 93; BioLegend) was routinely used to block Fc receptors before 
staining, and cell nuclei were stained with Hoechst 33258 (Invitrogen). 
Mouse anti–ZO-1 mAb (clone T8-754 [Itoh et al., 1991]; provided by   
M. Furuse, Kobe University, Kobe, Japan), anti-Dsg1 scFVs mAb with a 
hemagglutinin tag (provided by K. Ishii, Teikyo University Chiba Medical 
Center, Ichihara, Japan; Ishii et al., 2008), and an antihemagglutinin mAb 
were used for cryosection staining (3F10; Roche). Goat anti–E tag poly-
clonal  antibody  (Abcam)  and  horseradish  peroxidase–conjugated  donkey 
anti–goat IgG polyclonal antibody were used for immunoblotting.
Preparation and staining of epidermal and dermal sheets and cryo-
sections. Epidermal and dermal sheets were prepared with 3.8% ammonium 
thiocyanate (Wako) in 100 mM sodium phosphate (Nagao et al., 2009). Sheets 
were fixed in cold acetone and blocked with 3% skim milk (Morinaga), 
anti-CD16/32 mAb, and goat serum (Jackson ImmunoResearch Laborato-
ries, Inc.) in PBS before incubation with primary antibody overnight at 4°C. 
Consistent with the data in Fig. 1, patch immunization with 
ETA led to anti-ETA IgG1 production (Fig. 3 A). Immuniza-
tion with OVA i.p. resulted predominantly in IgG1 production, 
whereas  immunization  with  ETA  i.p.  induced  robust  IgG1, 
IgG2b, and IgG2c responses, in contrast to the IgG1-restricted 
responses induced by ETA patch immunization (Fig. 3 A and 
Fig. S2). This further supports a role for LCs in driving the Th2 
response (Nagao et al., 2009). Importantly, Langerin-DTR mice 
that were DT treated before each patch immunization failed to 
mount ETA-specific IgG1 responses (Fig. 3 A).
To functionally characterize LC-induced anti-ETA IgG1, 
we purified IgG from PBS (PBS-IgG) or ETA (ETA-IgG) 
patch-immunized  mice  and  determined  its  effect  on  the 
Dsg1-cleaving activity of ETA in vitro. Incubation of soluble 
human recombinant Dsg1 (hrDsg1) with ETA leads to efficient 
cleavage in vitro (Amagai et al., 2000). Although preincubation 
of PBS-IgG with ETA had no effect on hrDsg1 cleavage by 
ETA, the coincubation of ETA-IgG and ETA resulted in a 
marked decrease in the amount of cleaved hrDsg1 (Fig. 3 B), 
in a dose-dependent manner (Fig. 3 C), demonstrating that 
ETA-IgG exerts neutralizing activity toward ETA.
Finally, to directly demonstrate the in vivo role of LC-
induced IgG1, we challenged patch-immunized mice with 
a single i.p. injection of ETA (200 µg/body). The PBS-
immunized mice developed skin erosions (Fig. 3 D, top), but 
the majority of ETA patch-immunized mice were protected 
from developing SSSS (Fig. 3 D, middle). In stark contrast, 
Langerin-DTR mice treated with DT before each immunization 
developed SSSS (Fig. 3 D, bottom), with skin erosion indices 
significantly higher than those of ETA patch-immunized mice 
(Fig. 3 E). These results established the essential role of LCs in 
the induction of humoral responses that conferred systemic 
protection against circulating toxin in this model of SSSS.
Collectively, ACT by LCs led to the induction of hu-
moral immunity against ETA in the presence of an intact TJ 
barrier, and this immunity protected mice from developing 
experimental SSSS upon systemic ETA challenge. This study 
reveals a novel preemptive role for LCs in protective hu-
moral immunity in vivo against bacteria-derived pathogenic 
components that exist on the skin surface but have not yet 
breached the epidermal barrier. The protein antigens used in 
this study do not reach the viable epidermal layers, and how 
B cells in the draining lymph nodes recognize them is an   
interesting question to be clarified in future studies.
Vaccine development to date has focused on overcoming 
the epidermal barrier, using a variety of physical forces such as a 
gene gun and microneedles (Prausnitz et al., 2009; Yager et al., 
2009). The current work shows that this may not be essential. 
Targeting ACT by LCs can be extended to other toxins or 
pathogens and should have a marked impact on the strategies by 
which topical vaccines are designed to achieve defined systemic 
humoral immunity, with minimal invasiveness and stress.
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to challenge via i.p. injection. Abdominal skin, divided into three parts, was gently 
rubbed once with the right index finger 3 h after ETA challenge to observe 
epidermal detachment (Nikolsky’s sign). The skin erosion area was quantified as 
several pixels, using ImagePro version 6.3 (Media Cybernetics), and this number 
was divided by the total pixel number of the entire abdominal area.
In vitro Dsg1 cleavage assay. A Melon Gel IgG Purification System (Thermo 
Fisher Scientific) was used to obtain purified IgG from sera of mice that were 
patch immunized with ETA or PBS. The entire extracellular domain of hrDsg1 
with an E tag on the carboxyl terminus was produced as a secreted protein, 
using the baculovirus system as described previously (Amagai et al., 2000; Ishii 
et al., 1997). 20 µl of recombinant ET (4 µg/ml) was preincubated with   
20 µl of purified IgG for 1 h at 37°C and then with 1 µg hrDsg1 in 10 µl PBS 
containing 1 mM CaCl2 for 1 h. The digested samples were subjected to SDS-
PAGE and transferred to polyvinylidene fluoride membranes (Bio-Rad Lab-
oratories). Bands were detected using anti–E tag antibody and visualized with a 
chemiluminescent substrate (ECL Plus; GE Healthcare), followed by exposure 
to Kodak BioMax film (VWR international).
Statistical analysis. Statistical analysis was performed with the Student’s t 
test using Prism version 5 (GraphPad Software), and p-values ≤0.05 were re-
garded as significant.
Online supplemental material. Fig. S1 shows the generation of mice that 
lack langerin+ dDCs. Fig. S2 shows that the humoral response induced by 
LCs subsequent to ACT is restricted to IgG1. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20111718/DC1.
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